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Key message 
To our knowledge, this is the first report looking into the genetic differences between 
screen-detected and interval cancers not detected at screening. It is an affirmation that screen-
detected and interval cancers may have unique underlying biology, and our results have made 
advance in our understanding of genetic susceptibility to these distinct breast cancers. We 
believe that genetic risk discrimination has potential relevance in clinical care where interval 






Polygenic risk profiles computed from multiple common susceptibility alleles for breast 
cancer have been shown to identify women at different levels of breast cancer risk. We 
evaluated whether this genetic risk stratification can also be applied to discriminate between 
screen-detected and interval cancers, which are usually associated with 
clinicopathological and survival differences. 
Patients and methods 
A 77-SNP polygenic risk score (PRS) was constructed for breast cancer overall and by 
estrogen-receptor (ER) status. PRS was inspected as a continuous (per standard deviation 
increment) variable in a case-only design. Modification of the PRS by mammographic density 
was evaluated by fitting an additional interaction term. 
Results 
PRS weighted by breast cancer overall estimates was found to be differentially associated 
with 1,865 screen-detected and 782 interval cancers in the LIBRO-1 study (age-adjusted 
ORperSD [95% confidence interval]=0.91 [0.83-0.99], p=0.023). The association was found to 
be more significant for PRS weighted by ER-positive breast cancer estimates (ORperSD=0.90 
[0.82-0.98], p=0.011). This result was corroborated by two independent studies (combined 
ORperSD=0.87 [0.76-1.00], p=0.058) with no evidence of heterogeneity. When enriched for 
“true” interval cancers among nondense breasts, the difference in the association with PRS in 
screen-detected and interval cancers became more pronounced (ORperSD=0.74 [0.62-0.89], 
p=0.001), with a significant interaction effect between PRS and mammographic density 
(pinteraction=0.017). 
Conclusion 
To our knowledge, this is the first report looking into the genetic differences between screen-
detected and interval cancers. It is an affirmation that the two types of breast cancer may have 
unique underlying biology. 





A recent effort carried out by the Breast Cancer Association Consortium (BCAC), as 
part of the Collaborative Oncological Gene-Environment Study (COGS), has resulted in the 
collective identification of more than 40 new single nucleotide polymorphisms (SNPs), which 
nearly doubled the number of known susceptibility loci, and identified additional risk-
associated variants specific to estrogen receptor (ER)-negative breast cancer [1, 2]. On an 
unpredecented scale in breast cancer genetics, the collaborative large-scale experiment 
involved over 40,000 breast cancer cases and 40,000 controls [2]. 
Empirical studies suggest that individual risk loci underlying complex genetic diseases 
confer small effect sizes, with most genotype relative risks in the range of 1.1–2.0 [3]. 
However, the combined effect of common variants en masse may collectively account for a 
substantial proportion of variation in risk that is useful for population-based programmes of 
breast cancer prevention and early detection [4, 5].  
Polygenic risk scores (PRS) have recently been used to pool genetic effects among an 
ensemble of markers which are individually associated with small relative risks [6]. In a 
report by Mavaddat et al. [7], it was shown that PRS computed from the 77 genetic variants 
which reflect the state of the art GWAS findings of breast cancer stratifies breast cancer risk 
in women with and without family history of breast cancer [7]. A three-fold increased risk of 
developing breast cancer was found between women profiled in the highest 1% of the PRS, 
compared to the middle quintile. 
Whilst the PRS is likely to be an important tool for the risk prediction of breast cancer 
overall, breast cancer itself is not just one disease. Breast cancers which develop within the 
time interval between screening examinations (interval cancers) are usually associated with 
more adverse biological features and poorer survival outcomes compared with breast cancers 
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that are diagnosed through routine screening mammography (screen-detected cancers) [8, 9]. 
After adjusting for age and screening interval, interval cancers are typically larger, more 
frequently node-positive at diagnosis, more likely to be of lobular histology and more often 
associated with a triple-negative phenotype [8]. Although errors by radiologists generally 
account for about 25% to 40% of interval cancers [10] (22% in the Stockholm screening 
program [11]), another explanation is that the rapidly growing, high-grade tumor has a 
different biology and was too small to be detected on the last mammogram [12, 13].  
 
In view of a need to distinguish the generally more aggressive tumours of interval 
cancers, which benefit little from mammography screening, from screen-detected cancers, this 
paper uses PRS to explore whether there is a genetic difference between them. We examine 
whether the genetic risk stratification of breast cancer by PRS can also be applied to 
discriminate tumours with different biology. Due to a possible masking effect in dense 
breasts, it has been suggested that interval cancers are only truly more aggressive than screen-
detected cancers in nondense breasts [14]. Therefore, we also examined whether the 
association between PRS and detection mode is modified by mammographic density. 
Patients and methods 
Study subjects  
The primary analyses were based on the Linné-Bröst 1 (LIBRO-1) study; a cohort of 
Swedish female breast cancer cases. All first instances of female incident primary breast 
cancer cases diagnosed in Stockholm from January 2001through December 2008 (n=11,696) 
were identified via the Regional Cancer Register. We excluded women who were outside the 
age range of between 40 to 72 years at diagnosis of breast cancer (n=1,249), and excluded 
those who were deceased (n=645) or without a contact address (n=454) at point of 
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recruitment. Exclusions were motivated by the upper age bound of the screening program and 
the possibility to receive informed consent. A total of 9,348 women remained in the study 
base and were invited to participate. Invitations were sent out early in 2009 together with 
study information, informed consent documents, blood sampling tubes and a link to our web-
questionnaire. Informed consent was retrieved for 61% (n=5,715) of the invited population. 
Cancer-free controls were comprised of 5,537 participants of the Karolinska 
Mammography Project for Risk Prediction of Breast Cancer (KARMA) mammography 
screening study (http://karmastudy.org/) recruited between 2010 and 2011 from Helsingborg 
and Stockholm in Sweden. 
Genotyping 
Samples from LIBRO-1 and KARMA were genotyped using a custom Illumina iSelect 
Array (iCOGS) comprising 211,155 SNPs. The 77 breast cancer SNPs [7] were based 
primarily on variants reported to be associated at a genome-wide level (P<5×10-8) by COGS 
or previous publications, with either breast cancer overall or diseases of different ER 
subtypes. Missing genotypes were imputed using 1000 Genomes (Phase I integrated variant 
set release (v3) in NCBI build 37 (hg19) coordinates). 
Mammographic screening visits and mammographic density 
Dates of mammographic screening visits and information about the outcome of each 
visit were obtained through merges to the mammography-screening database kept at the 
Stockholm-Gotland Regional Cancer Center [15]. The database contains attendance and 
outcome of all visits undertaken within the population-based mammography-screening 
program for Stockholm County. Since 1989, all Stockholm women ages 50-69 have been 
invited to screening at 24-month intervals. Women 40-49 were included since mid-2005, 
invited with 18-month intervals. 
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Screen-film mammograms were collected from radiology departments and digitized 
with an Array 2905HD Laser Film Digitizer (Array Corp, Tokyo, Japan). Percentage 
mammographic density (PD) was estimated with an ImageJ-based method previously 
described in [16]  for pre-diagnostic images in the mediolateral oblique view of the cancer-
free breast. Women who developed contralateral cancer within three months of diagnosis did 
not have their mammographic density measured. Missing values of PD were replaced by the 
medians of all known values of the respective variables.  
After excluding women diagnosed without a prior screening visit (n=1,701), women 
diagnosed after a normal screening interval had passed (n=1,014) and 99 cases with uncertain 
method of detection, 2,901 interval- or screen-detected tumors were identified within the 
study period. Of these women, 2,647 (1,865 screen-detected and 782 interval cancers) were 
successfully genotyped on iCOGS. 
Polygenic risk score (PRS) 
To investigate the association between breast cancer risk and the joint effects of known 
breast cancer loci, we combined the 77 SNPs by summing the number of alleles of each SNP, 
weighted by the effect sizes reported in Mavaddat et al. [7] (Supplementary Table S1, 
available at Annals of Oncology online).  A PRS was derived for each individual using the 
formula below [7]: 
PRS=β1x1 + β2x2 + … + βkxk + … + βnxn 
Where βk is the per-allele odds ratio (OR) for breast cancer associated with the minor allele 
for SNP k, and xk the number of alleles for the same SNP (0, 1 or 2), and n=77 is the total 
number of SNPs. Three separate PRS were constructed, corresponding to weights from breast 
cancer overall (PRSoverall), estrogen receptor (ER)-negative (PRSER-neg), and ER-positive 
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disease (PRSER-positive). SNP ORs estimated separately for each ER subtype in the iCOGS 
experiment were used to derive the subtype-specific PRS [7]. 
Supporting datasets 
Replication of the findings was performed in two independent datasets: Sweden and 
Singapore Breast Cancer Study (SASBAC) [2] and MERCK [17]. Briefly, SASBAC is a 
population-based case-control study of postmenopausal breast cancer in women aged 50 to 74 
years born in Sweden, and diagnosed between 1 October 1993 and 31 March 1995. 
Genotyping for the SASBAC dataset was performed on the iCOGS array.  
The patient cohort of the MERCK study was selected using the population-based 
Stockholm-Gotland Breast Cancer Registry and the unique 12-digit personal number assigned 
to each Swedish resident. Women who were diagnosed with a primary breast cancer from 
January 1, 1997 through December 31, 2005, were identified. Patients developing distant 
metastatic diseases were selected and matched with metastasis-free breast cancer cases by 
adjuvant therapy, age and calendar period at diagnosis. Due to the enrichment for deadly 
metastatic breast cancers, the study has a comparatively larger proportion of interval cancers 
and higher number of excluded individuals due to young age (before screening age) compared 
to SASBAC and LIBRO-1. Genotyping for the MERCK study was performed on the 
Human1M-Duo BeadChip array.  
All study participants gave informed consent and all studies were approved by the 
ethical committee at Karolinska Institutet. 
Statistical methods 
We first explored the relationship between PRS and breast cancer risk stratified by 
screen-detected/interval cancer status in the two case-control studies, LIBRO-1/KARMA and 
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SASBAC. Logistic regression models were used to estimate the 1) ORs and corresponding 
95% confidence intervals (CI) for breast cancer risk by quartiles of the PRS based on controls, 
with the lowest quartile as the reference, or 2) the ORs and corresponding 95% CI associated 
with one standard deviation (SD) increments for PRS as a continuous variable. Analyses were 
adjusted for age at diagnosis for cases, or age at interview for controls. 
To test for heterogeneity between screen-detected and interval cancers, we used a case-
only design, comparing the two groups of breast cancer patients separated according to 
screen-detected/interval cancer status.  Breast cancers detected at a screening visit were 
compared to breast cancers detected clinically in the interval between two screens.  
Logistic regression models were used to estimate the ORs and corresponding 95% CI 
for interval vs screen-detected cancers by quartiles of the PRS based on screen-detected breast 
cancers, with the lowest quartile as the reference. Continuous PRS was standardized and the 
ORs and corresponding 95% CI associated with one standard deviation (SD) increments were 
also estimated. We adjusted for age at diagnosis, and PD. Modification of the PRS by PD 
(nondense [PD<25%] or dense [PD≥25%]) was evaluated by fitting an additional interaction 
term in the model. All tests of statistical significance were two-sided. All statistical analyses 
were carried out using the program R (Foundation for Statistical Computing, Vienna, 
Austria). 
Results 
The distributions of PRS by dataset are given in Supplementary Table S2 (available at 
Annals of Oncology online). In two independent case-control studies, PRSoverall was found to 
be significantly associated with both screen-detected and interval cancers when compared 
against cancer-free controls, with an increased breast cancer risk for every increase in 
PRSoverall quartile (Supplementary Table S3, available at Annals of Oncology online). When 
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we tested for heterogeneity using a case-only design, PRSoverall was found to be differentially 
associated with 1,865 screen-detected and 782 interval cancers in the LIBRO-1 study (age-
adjusted ORperSD [95% CI]=0.91 [0.83 to 0.99], p=0.023, Table 1). The association was found 
to be more significant for PRSER-pos (ORperSD=0.90 [0.82 to 0.98], p=0.011), but not 
significant for PRSER-neg (ORperSD=1.02 [0.94 to 1.11], p=0.687). This result was corroborated 
by two independent studies with smaller sample sizes showing a clear trend with effects in the 
same direction and magnitude (Table 2, combined ORperSD=0.87 [0.76 to 1.00], p=0.058) with 
no evidence of heterogeneity.  
When PRSoverall was categorized by quartiles based on the distribution in screen-
detected cancers, patients were observed to be less likely interval cancers compared to screen-
detected cancers with each increased quartile of PRSoverall (Table 1). Women with the highest 
quartile of PRSoverall were 20% less likely to be interval cancer cases (OR=0.80, 95% CI: 0.63 
to 1.01, p=0.066), after adjusting for age at diagnosis. The association persisted after we 
adjusted for mammographic density. No discernible trend was observed for each increase in 
PRSER-neg quartile. 
The relationship between PRS and screen-detected/interval cancer status was found to 
change depending on whether the affected woman has dense (PD≥25%) or nondense 
(PD<25%) breasts, for both PRSoverall and PRSER-pos (Table 3, pinteraction=0.031 and 0.017, 
respectively). The corresponding observed effect sizes in nondense breasts were more 
pronounced than those observed in dense breasts (PRSoverall: ORperSD=0.77 [0.64 to 0.92], 
p=0.004 for nondense breasts vs ORperSD=0.97 [0.86 to 1.09], p=0.633 for dense breasts; 
PRSER-pos: ORperSD=0.74 [0.62 to 0.89], p=0.001 for nondense breasts vs ORperSD=0.97 [0.86 





In this study, we explored whether genetic data for 77 common breast cancer variants, 
summarized as a PRS, could discriminate between screen-detected and interval cancers. The 
positive association between breast cancer risk and PRS reported by Mavaddat et al. [7] was 
found to hold true for both screen-detected and interval cancers when compared to controls 
(Supplementary Table S3, available at Annals of Oncology online). In a case-only analysis, 
interval cancers were found to be associated with lower PRSoverall/ER-pos in our primary 
Swedish dataset (LIBRO-1), and the results were corroborated by two smaller Swedish 
datasets, SASBAC and MERCK, with comparable beta estimates in the same direction. 
Results of the analyses on PRSoverall and PRSER-pos were found to be largely similar, tending 
towards a decreased risk of being an interval cancer over screen-detected cancer for each 
increased quartile of PRS (Tables 1 and 3). No clear trend was observed between quartiles of 
PRSER-neg and screen-detected/interval cancer status (Tables 1-3). The relationships between 
PRSoverall/ER-pos and screen-detected/interval cancer status were found to be significantly 
different in breasts of high or low density, with much larger effect sizes observed in nondense 
breasts (Table 3). 
Whilst much work has been performed to compare the clinic-pathological 
characteristics, molecular biomarkers and survival outcomes of screen-detected and interval 
cancers [8, 9, 12, 13, 18-20], there is yet a study which examines for germline genetic 
variation between screen-detected and interval cancers. Within the available 77-SNP 
portfolio, we observed disparate associations between screen-detected and interval cancers, 
suggesting that screen-detected and interval cancers are indeed distinct in both underlying 
genetics and biology. Replications from two independent studies provide further evidence that 
screen-detected and interval cancers have different genetic profiles.  
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True interval cancers are defined as an interval cancer with a normal screening 
mammogram, with no reason for assessment, as opposed to false-negative examinations 
missed at a previous mammography [10]. Due to a possible masking effect in dense breasts, it 
has been suggested that interval cancers are only truly more aggressive than screen-detected 
cancers in nondense breasts [14, 18, 19]. We stratified the dataset into women with dense and 
nondense breasts to explore if the association between PRS and screen-detected/interval 
cancer status would be stronger among those with nondense breasts, which is likely to be 
enriched for true interval cancers. In agreement, the effect sizes and associated statistical 
significance we observed among women with low mammographic density were more 
pronounced than that when we included all the women (Table 3). Taken at face value, women 
with nondense breasts and high PRSoverall/ER-pos were more likely to be associated with the 
more favourable screen-detected breast cancer.  
At a tipping point of genetic discoveries for breast cancer, a study that looks into 
stratifying the disease further into distinct subtypes is timely. The examination of possible 
genetic differences between screen-detected and interval cancers is also novel. The major 
strength of this study is the extensive national registry data available in Sweden, which offers 
an unprecedented and unparalleled resource to look into a study population that represents a 
large sample of the Swedish population. Whilst screen-detected and interval cancers differ 
primarily in their method of detection, the proper and accurate definition of latter is highly 
dependent on a comprehensive screening history, which is made possible with the nationwide 
mammography screening programme in Sweden implemented several decades ago. We have 
also incorporated the use of the most comprehensive and updated, state-of-the-art list of breast 
cancer susceptibility loci to date in the construction of PRS.  
A noteworthy limitation is that the list of SNPs is mostly restricted to the iCOGS chip 
(41 out of 77), which was heavily enriched for SNPs with prior evidence of association with 
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breast cancer as a whole. The existence of other loci that have not been harvested by the 
iCOGS chip or previous breast cancer GWAS thus cannot be dismissed. Future studies using 
SNP arrays with genome-wide coverage are thus warranted. In addition, depending on the 
local screening guidelines, the definition of interval cancer can be inconsistent, with the time 
interval between screening mammograms ranging from one to three years [21, 22]. Whilst we 
observed similar effect sizes across three independent Swedish studies where the screening 
interval is two years for the majority of the women, it is unclear whether our results are 
generalizable over varied definitions of interval cancer. It should be also be highlighted that 
interval cancers have similar features and outcomes as symptomatically-presenting cases (i.e. 
they are similar, not worse, in terms of outcome, as clinically-presenting women who did not 
screen) [23]. However, the studies which have compared interval cancers and symptomatic 
cancers to screen-detected cancers have been small in size and have not made clear 
distinctions between dense/nondense, or true/false-negative interval cancers. Future work can 
expand our understanding on whether such cases are also genetically different. 
To our knowledge, this is the first report looking into the genetic differences between 
screen-detected and interval cancers. It is an affirmation that screen-detected and interval 
cancers may have unique underlying biology, and our results have made advance in our 
understanding of genetic susceptibility to these distinct breast cancers. We believe that genetic 
risk discrimination has potential relevance in clinical care where interval cancers, which are 
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Table 1. Association between polygenic risk score (PRS) and screen-detected or interval breast cancer. Abbreviations: Screen, screen-detected; pWald, Pvalue 
based on Wald test. 
        
Univariate  Adjusted for age  Adjusted for age and PD 
PRS quartile (range) Screen Interval   OR 95% CI pWald   OR 95% CI pWald   OR 95% CI pWald 
PRSOverall                             
     Q1 (-3.277 to -0.659) 466 223   1.00 Reference     1.00 Reference     1.00 Reference   
     Q2 (-0.659 to -0.012) 466 192   0.86 0.68 to 1.09 0.206   0.86 0.68 to 1.08 0.201   0.87 0.69 to 1.10 0.234 
     Q3 (-0.011 to 0.652) 466 188   0.84 0.67 to 1.06 0.150   0.85 0.67 to 1.07 0.157   0.84 0.66 to 1.06 0.145 
     Q4 (0.652 to 3.720) 467 179   0.80 0.63 to 1.01 0.064   0.80 0.63 to 1.01 0.066   0.82 0.65 to 1.04 0.110 
     Continuous variable 1865 782   0.91 0.83 to 0.99 0.022   0.91 0.83 to 0.99 0.023   0.91 0.84 to 0.99 0.036 
                              
PRSER-neg                             
     Q1 (-3.664 to -0.718) 466 197   1.00 Reference     1.00 Reference     1.00 Reference   
     Q2 (-0.717 to -0.04) 466 207   1.05 0.83 to 1.33 0.678   1.05 0.83 to 1.33 0.669   1.07 0.85 to 1.36 0.568 
     Q3 (-0.04 to 0.621) 466 180   0.91 0.72 to 1.16 0.460   0.91 0.72 to 1.16 0.458   0.92 0.72 to 1.18 0.519 
     Q4 (0.621 to 3.392) 467 198   1.00 0.79 to 1.27 0.981   1.01 0.79 to 1.27 0.961   1.01 0.79 to 1.28 0.944 
     Continuous variable 1865 782   1.02 0.94 to 1.11 0.687   1.02 0.94 to 1.11 0.677   1.02 0.94 to 1.11 0.685 
                              
PRSER-pos                             
     Q1 (-3.482 to -0.665) 466 218   1.00 Reference     1.00 Reference     1.00 Reference   
     Q2 (-0.664 to -0.01) 466 197   0.90 0.72 to 1.14 0.391   0.90 0.71 to 1.14 0.374   0.90 0.71 to 1.14 0.391 
     Q3 (-0.010 to 0.672) 466 189   0.87 0.69 to 1.09 0.230   0.87 0.69 to 1.10 0.242   0.86 0.68 to 1.09 0.213 
     Q4 (0.673 to 3.777) 467 178   0.81 0.64 to 1.03 0.089   0.82 0.64 to 1.03 0.091   0.83 0.66 to 1.06 0.132 
     Continuous variable 1865 782   0.90 0.82 to 0.97 0.011   0.90 0.82 to 0.98 0.011   0.90 0.83 to 0.98 0.020 
 
 
Table 2. Association between polygenic risk score (PRS) and screen-detected or interval breast cancer in independent studies. Abbreviations: 




     Univariate  Adjusted by age 
 Screen Interval   OR 95% CI pWald   OR 95% CI pWald 
PRSOverall                     
     SASBAC 694 197   0.88 0.75 to 1.03 0.106   0.87 0.74 to 1.03 0.102 
     MERCK 95 98   0.92 0.68 to 1.23 0.559   0.92 0.68 to 1.23 0.556 
     Combined  789  298   0.89 0.77 to 1.02 0.090   0.88 0.77 to 1.02 0.086 
     I2=0; pHet=0.794  I2=0; pHet=0.787 
                      
PRSER-neg                     
     SASBAC 694 197   0.98 0.84 to 1.15 0.805   0.98 0.84 to 1.15 0.804 
     MERCK 95 98   0.97 0.72 to 1.31 0.857   0.97 0.72 to 1.31 0.857 
     Combined  789  298   0.98 0.85 to 1.13 0.762   0.98 0.85 to 1.13 0.761 
          I2=0; pHet=0.966   I2=0; pHet=0.967 
           
PRSER-pos                     
     SASBAC 694 197   0.86 0.73 to 1.01 0.067   0.86 0.73 to 1.01 0.064 
     MERCK 95 98   0.92 0.68 to 1.24 0.575   0.92 0.68 to 1.24 0.572 
     Combined  789  298  0.87 0.76 to 1.01 0.061  0.87 0.76 to 1.00 0.058 
     I2=0; pHet=0.706  I2=0; pHet=0.702 
 
 
Table 3. Association between polygenic risk score (PRS) and screen-detected or interval breast cancer, age-adjusted and stratified by percent mammographic density (PD). 
Abbreviations: Screen, screen-detected; pWald, Pvalue based on Wald test; pinteraction, Pvalue for interaction between percent mammographic density (dense/nondense) and PRS 
as a continuous variable. 
  Nondense (PD<25%)   Dense (PD≥25%)     
 PRS quartile (range) Screen Interval OR 95% CI pWald   PRS quartile (range) Screen Interval OR 95% CI pWald   pnteraction 
PRSOverall                               
  Q1 (-3.277 to -0.634) 155 46 1.00 Reference     Q1 (-3.243 to -0.713) 220 104 1.00 Reference       
  Q2 (-0.632 to 0.012) 155 39 0.85 0.52 to 1.37 0.502   Q2 (-0.713 to -0.059) 220 113 1.09 0.78 to 1.50 0.623     
  Q3 (0.013 to 0.749) 155 41 0.89 0.55 to 1.43 0.631   Q3 (-0.058 to 0.567) 220 92 0.89 0.63 to 1.25 0.494     
  Q4 (0.751 to 3.71) 155 27 0.59 0.35 to 0.99 0.047   Q4 (0.567 to 3.419) 220 112 1.08 0.78 to 1.49 0.648     
  Continuous variable 620 153 0.77 0.64 to 0.92 0.004   Continuous variable 880 421 0.97 0.86 to 1.09 0.633   0.031 
                                
PRSER-neg                               
  Q1 (-2.802 to -0.688) 155 46 1.00 Reference     Q1 (-3.664 to -0.742) 220 96 1.00 Reference       
  Q2 (-0.684 to -0.08) 155 31 0.67 0.41 to 1.12 0.127   Q2 (-0.739 to -0.032) 220 123 1.28 0.93 to 1.78 0.132     
  Q3 (-0.079 to 0.569) 155 30 0.65 0.39 to 1.09 0.101   Q3 (-0.028 to 0.623) 220 102 1.06 0.76 to 1.49 0.718     
  Q4 (0.572 to 3.011) 155 46 1.00 0.63 to 1.60 0.987   Q4 (0.625 to 3.392) 220 100 1.05 0.75 to 1.47 0.785     
  Continuous variable 620 153 1.00 0.83 to 1.21 0.962   Continuous variable 880 421 1.02 0.91 to 1.14 0.702   0.860 
                                
PRSER-pos                               
  Q1 (-3.482 to -0.630) 155 49 1.00 Reference     Q1 (-3.311 to -0.711) 220 108 1.00 Reference       
  Q2 (-0.627 to 0.039) 155 43 0.88 0.55 to 1.40 0.589   Q2 (-0.711 to -0.073) 220 98 0.91 0.65 to 1.26 0.560     
  Q3 (0.046 to 0.759) 155 33 0.67 0.41 to 1.10 0.115   Q3 (-0.072 to 0.564) 220 102 0.95 0.68 to 1.32 0.761     
  Q4 (0.761 to 3.777) 155 28 0.57 0.34 to 0.96 0.033   Q4 (0.566 to 3.206) 220 113 1.05 0.76 to 1.45 0.768     
  Continuous variable 620 153 0.74 0.62 to 0.89 0.001   Continuous variable 880 421 0.97 0.86 to 1.09 0.579   0.017 
 
 
